| Literature DB >> 32624689 |
Vojko Kanic1, Robert Ekart1, Zlatka Kanic1.
Abstract
Background: Data on acute kidney injury (AKI) in patients with myocardial infarction (MI) who underwent percutaneous coronary intervention (PCI) after cardiac arrest are scarce. The prevalence of AKI, as classified by the Kidney Disease: Improving Global Outcomes (KDIGO) criteria; and its possible association with 30-day mortality were assessed.Entities:
Keywords: acute kidney injury; cardiac arrest; myocardial infarction; outcome; percutaneous coronary intervention; resuscitation
Mesh:
Substances:
Year: 2020 PMID: 32624689 PMCID: PMC7330674 DOI: 10.7150/ijms.45686
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Figure 1The diagram shows the number of MI patients screened, excluded and enrolled in the study. AKI: acute kidney injury; MI: myocardial infarction, PCI: percutaneous coronary intervention.
Basic patient characteristics
| AKI; N = 93 | No AKI; N = 249 | p | |
|---|---|---|---|
| Age, years∞ | 66.0 (12.5) | 61.8 (11.8) | 0.029 |
| Male gender, N (%)* | 67 (72.0) | 177 (71.1) | 0.89 |
| ST-elevation MI, N (%)* | 83 (89.2) | 215 (86.3) | 0.59 |
| Diabetes, N (%)* | 25 (26.9) | 35 (14.1) | 0.01 |
| Hypertension, N (%)* | 45 (48.4) | 109 (43.8) | 0.46 |
| Hyperlipidemia, N (%)* | 18 (19.4) | 86 (34.5) | 0.008 |
| Renal dysfunction, N (%)* | 46 (49.5) | 53 (25.3) | <0.0001 |
| Cardiogenic shock, N (%)* | 37 (39.8) | 48 (19.3) | <0.0001 |
| Mechanical ventilation, N (%)* | 63 (67.7) | 87 (34.9) | <0.0001 |
| Creatinine, mgl/dL¥ | 1.20 (0.94, 1.65) | 0.94 (0.79, 1.20) | <0.0001 |
| GFR, ml/kg/1.73m2 ¥ | 61.0 (40.6, 79.2) | 76.6 (61.2, 96.1) | <0.0001 |
| Mehran score, N∞ | 12.9 (5.4) | 8.66 (5.2) | <0.0001 |
| BMI, N∞ | 27.8 (4.5) | 27.4 (4.5) | 0.49 |
∞ Mean (standard deviation); * Comparison made using the chi-square test; ¥ Median (25th, 75th percentile).
BMI: body mass index; GFR: glomerular filtration rate; MI: myocardial infarction; N: number.
Procedural characteristics of patients
| AKI (N = 93) | No AKI (N = 249) | p | |
|---|---|---|---|
| Hypothermia, N (%)* | 49 (52.7) | 96 (38.6) | 0.08 |
| Contrast volume, ml¥ | 152.5 (114.7, 197.5) | 150.0 (112.0, 200.0) | 0.89 |
| Contrast volume-to-GFR ratio¥ | 2.66 (1.67, 4.19) | 1.90 (1.34, 2.90) | 0.001 |
| Bivalirudin, N (%)* | 6 (6.5) | 40 (16.1) | 0.02 |
| GPIIb/IIIa, N (%)* | 58 (52.4) | 133 (53.4) | 0.14 |
| Dual antiplatelet therapy, N (%)* | 63 (67.7) | 221 (88.8) | <0.0001 |
| PCI LMCA, N (%)* | 8 (8.6) | 13 (5.2) | 0.31 |
| PCI LAD, N (%)* | 45 (46.4) | 115 (46.2) | 0.72 |
| PCI LCX, N (%)* | 26 (28.0 ) | 57 (22.9) | 0.33 |
| PCI RCA, N (%)* | 21 (22.6) | 72 (28.9) | 0.28 |
| Radial access, N (%)* | 5 (5.4) | 23 (9.2) | 0.37 |
| IABP, N (%)* | 11 (11.8) | 13 (5.2) | 0.054 |
| TIMI flow 0/1 after PCI, N (%)* | 17 (6.8) | 11 (11.8) | 0.18 |
| BARC 3a bleeding, N (%)* | 52 (55.9) | 69 (27.7) | <0.0001 |
| Heart failure, N (%)* | 76 (81.7) | 123 (53.4) | <0.0001 |
| Peak troponin, (mol/L) ¥ | 40.92 (8.3, 84.3) | 24.26 (6.7, 65.6) | <0.0001 |
| Ejection fraction, (%)∞ | 33.2 (7.3) | 39.2 (9.9) | <0.0001 |
| Renal replacement therapy, N (%)* | 14 (15.1) | 0 (0) | <0.0001 |
∞ Mean (standard deviation);* Comparison made using the chi-square test; ¥ Median (25th, 75th percentile).
AKI: acute kidney injury; BARC: Bleeding Academic Research Consortium; GFR: glomerular filtration rate; GPIIb/IIIa: GPIIb/IIIa receptor inhibitor; IABP: intra-aortic balloon pump; LAD: left anterior descending artery; LCX: circumflex artery; LMCA: left main coronary artery; N: number; PCI: percutaneous coronary intervention; RCA: right coronary artery; TIMI 0/1: TIMI grade flow after PCI: 0/1.
Independent predictors of 30-day mortality
| Variable | OR | 95% CI | p |
|---|---|---|---|
| AKI | 6.98 | 3.42 to 14.23 | <0.0001 |
| Bleeding | 2.47 | 1.18 to 5.17 | <0.0001 |
| Cardiogenic shock | 2.82 | 1.38 to 5.75 | 0.004 |
| Female sex | 2.46 | 1.21 to 5.01 | 0.013 |
| Contrast volume-to-GFR ratio | 1.33 | 1.08 to 1.63 | 0.007 |
AKI: acute kidney injury; GFR: glomerular filtration rate.